facebook twitter linkedin
  • images/stories/slider.png
  • images/stories/slider2.png
  • images/stories/slider3.png
  • images/stories/slider4.png

NEWS RELEASES

  • Selvita initiates IND-enabling Studies for its first-in-class PIM/FLT3 inhibitor

    Krakow, 31 March 2015 - Selvita (WSE:SLV), the largest drug discovery company in Central and Eastern Europe, announced today that it is commencing IND-enabling studies for SEL24 project, the company’s first oncology drug candidate. &n SEL24 is a nov…

    Read More...

  • Selvita doubled its revenues and achieved full-year profitability in 2014

    Kraków, 19 March 2015 - Selvita, the largest drug discovery company in Central and Eastern Europe, achieved its best ever revenues and first-ever full-year operating profit in 2014. Revenue amounted to PLN 41.3 MM, which is a 90% increase from 2013 r…

    Read More...

  • Selvita expands its proteomics services offer

    Krakow, 16 March 2015 - Selvita, global integrated drug discovery partner for the pharmaceutical and biotechnology industries with offices in Greater Boston Area and Krakow, Poland, announced today that it has expanded its portfolio of protein chemis…

    Read More...